New Top Exec Reshuffle To Steer OGT Down Dx Path

Oxford Gene Technology has appointed its former head of R&D, John Anson, as CEO and brought in a new head of regulatory affairs, Paul Kenny, as the company shifts resources to the molecular diagnostics market.

UK specialist in genomic analysis and next-generation sequencing specialist Oxford Gene Technology Ltd. has promoted John Anson, its former EVP of R&D who has been at the company since 2006, to the role of CEO.

Anson takes over from Mike Evans, who has led the firm since 2005 and spearheaded its transformation from a microarray...

Welcome to Medtech Insight

Create an account to read this article

More from In Vitro Diagnostics

More from Diagnostics

Former Top OIG Attorney Gives Inside Look At Fraud Prevention

 
• By 

Former HHS-OIG attorney Rob DeConti emphasized the significance of data analytics and compliance in combating healthcare fraud, urging medical tech companies to adopt robust measures to prevent potential risks.

Medtronic’s ‘Strategic Expansion’ Into Remote Monitoring

 

“The Corsano wearable strengthens Medtronic’s acute care and monitoring portfolio,” Marc De Martini, vice president at Medtronic, told Medtech Insight.

No Strings Attached: Big Players Chase Insulet In Fast-Growing Tubeless Insulin Pump Market

 
• By 

Medtronic, Tandem and Beta Bionics are gearing up to bring tubeless patch pumps to market, chasing Insulet’s Omnipod 5, the only FDA-cleared patch pump for type 1 and type 2 diabetes. Analysts expect tubeless models to eventually displace durable pumps.